Aug 28, 2023 By Ivy Chen Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023
Jun 23, 2023 By Ivy Chen HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Jan 6, 2023 By Vincent Tse HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Nov 18, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Aug 15, 2022 By Rick Bowen HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
Jan 10, 2022 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001
Nov 1, 2021 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
Jun 17, 2021 By sarahjibrin FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
